AstraZeneca's New Oral GLP-1 Drug AZD0186 Passes Its First Human Test
Novel oral GLP-1 small molecule AZD0186 showed GLP-1 receptor activation, glucose-stimulated insulin secretion, and weight loss effects in preclinical and Phase 1 human testing.
Quick Facts
What This Study Found
AZD0186 activated GLP-1 receptors, stimulated insulin secretion, and reduced weight in preclinical models, with acceptable Phase 1 human safety.
Key Numbers
Doses 5-150 mg tested in humans; dose-dependent GSIS in animals and humans; no serious AEs reported.
How They Did This
Preclinical (cell lines, EndoC-βH5 cells, NHP, hGLP-1R mice) plus first-in-human randomized single ascending dose trial.
Why This Research Matters
Another oral GLP-1 drug entering the pipeline increases competition, which should improve access and reduce costs for patients.
The Bigger Picture
With multiple oral GLP-1 drugs now in Phase 1-3 (oral semaglutide, orforglipron, HDM1002, AZD0186), the competitive landscape is intensifying.
What This Study Doesn't Tell Us
Phase 1 single-dose data only — efficacy, chronic safety, and optimal dosing not yet established.
Questions This Raises
- ?How does AZD0186 compare to orforglipron in terms of bioavailability and efficacy?
- ?What differentiates AZD0186's mechanism from other oral GLP-1 small molecules?
Trust & Context
- Key Stat:
- Phase 1 complete AZD0186 first-in-human SAD trial demonstrates safety and pharmacokinetics for further development
- Evidence Grade:
- Combined preclinical and Phase 1 data — comprehensive early-stage development package.
- Study Age:
- Published in 2025, part of the accelerating oral GLP-1 drug development race.
- Original Title:
- Preclinical evaluation and first-in-human phase 1 trial of AZD0186, a novel, oral small molecule glucagon-like peptide-1 receptor agonist.
- Published In:
- The Journal of pharmacology and experimental therapeutics, 392(10), 103683 (2025)
- Authors:
- Qi, Weier, Boca, Simina M, Boianelli, Alessandro, Fredberg, Monica, Lundqvist, Sara, Davies, Graeme, Field, Joss, Brighton, Cheryl A, Snijder, Arjan, Grundevik, Pernilla, Eckernäs, Daniel, Träff, Annika Maria, Polla, Magnus, Pettersen, Daniel, Omar, Sami, Hansen, Lars, Janzén, David, Melin, Johanna, van Zuydam, Natalie, Logue, Jennifer, Wallenius, Kristina
- Database ID:
- RPEP-13139
Evidence Hierarchy
Frequently Asked Questions
What is AZD0186?
A new oral GLP-1 drug from AstraZeneca designed to be a convenient pill form alternative to injectable GLP-1 medications for diabetes and obesity.
How many oral GLP-1 pills are being developed?
Several, including oral semaglutide (approved), orforglipron, HDM1002, and AZD0186 — competition is expanding patient options.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13139APA
Qi, Weier; Boca, Simina M; Boianelli, Alessandro; Fredberg, Monica; Lundqvist, Sara; Davies, Graeme; Field, Joss; Brighton, Cheryl A; Snijder, Arjan; Grundevik, Pernilla; Eckernäs, Daniel; Träff, Annika Maria; Polla, Magnus; Pettersen, Daniel; Omar, Sami; Hansen, Lars; Janzén, David; Melin, Johanna; van Zuydam, Natalie; Logue, Jennifer; Wallenius, Kristina. (2025). Preclinical evaluation and first-in-human phase 1 trial of AZD0186, a novel, oral small molecule glucagon-like peptide-1 receptor agonist.. The Journal of pharmacology and experimental therapeutics, 392(10), 103683. https://doi.org/10.1016/j.jpet.2025.103683
MLA
Qi, Weier, et al. "Preclinical evaluation and first-in-human phase 1 trial of AZD0186, a novel, oral small molecule glucagon-like peptide-1 receptor agonist.." The Journal of pharmacology and experimental therapeutics, 2025. https://doi.org/10.1016/j.jpet.2025.103683
RethinkPeptides
RethinkPeptides Research Database. "Preclinical evaluation and first-in-human phase 1 trial of A..." RPEP-13139. Retrieved from https://rethinkpeptides.com/research/qi-2025-preclinical-evaluation-and-firstinhuman
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.